Drugs / CD30 CAR T-cell
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06617286 | Dec 2026 → Dec 2039 expected | classic Hodgkin lymphoma | New York Medical College | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD30 CAR T-cell | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06617286 ↗ |
| Known as | CD30+ CAR T-cells | “Patients with poor risk classical Hodgkin Lymphoma (cHL) will undergo myeloablative chemotherapy (MAC) with autologous stem cell transplantation (AutoHSCT) and subsequently...” NCT06617286 ↗ |
| Modality | Cell therapy | “CD30+ CAR T-cells” NCT06617286 ↗ |